ATOLL Shows IV Enoxaparin Improves Ischemic Outcomes in Primary PCI for STEMI

“Enoxaparin kind of rears its head once again as a superior drug – and this time with no increased bleeding,” commented former American College of Cardiology president Dr. W. Douglas Weaver in an interview.

“To be superior with MI as an end point, that’s pretty striking. I’m surprised. It’s fascinating. I can’t wait to see all the data. This could be practice changing. Enoxaparin is easier to use. People have been unwilling to use it in the cath lab because you just can’t measure the extent of anticoagulation. But as Professor Montalescot says, why do you need to measure it if you know that it’s perfect? I thought the data were quite impressive,” said Dr. Weaver of the Henry Ford Health System, Detroit.

The ATOLL study was sponsored by Assistance Publique-Hôpitaux de Paris with the help of a research grant from Sanofi-Aventis. Dr. Montalescot disclosed that he has received consulting and/or lecture fees from Sanofi-Aventis as well as more than a dozen others.